surpass 4 tirzepatide Lilly's achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial Tirzepatide: A Systematic Update
Pay in 4 interest-free payments of $7.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3




























